The potential for blood clots is behind Ariad Pharmaceuticals' decision to suspend sales of Iclusig, a drug used to treat leukemia.
The Massachusetts company was asked to stop marketing the drug by the Food and Drug Administration on Wednesday afternoon. Thursday, Ariad said it's in negotiations with the agency to change prescribing information and manage risks associated with the drug. The company said it wants to continue to market Iclusig.
Concerns over the side effects were released earlier this month, resulting in shares of Ariad losing three-quarters of their value. In premarket trading on Thursday, the stock dropped 43 percent to $2.24.
Iclusig was approved by the FDA in December to treat two rare types of leukemia.
All content © Copyright 2000 - 2014 WorldNow and WREX. All Rights Reserved.
Persons with disabilities who need assistance with issues relating to the content of this station's public inspection file should contact Administrative Assistant Trista Truesdale at (815) 335-7856. Questions or concerns relating to the accessibility of the FCC's online public file system should be directed to the FCC at 888-225-5322, at 888-835-5322 (TTY) or at email@example.com.